In the hunt for reverse merger targets, Caribou could be prized game

🇺🇸 BioPharma Dive (US) —
In the hunt for reverse merger targets, Caribou could be prized game

AI Summary

Cell therapy developer Caribou is exploring strategic alternatives as it struggles, making it a potential target for reverse-merger interest. The report describes possible corporate transaction interest rather than a completed deal.

The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a likely candidate to receive reverse merger interest.

Markets Deals Health Caribou Biosciences cell therapy reverse merger strategic alternatives biotechnology corporate transactions

Read original source →